Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: A human postmortem study

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1295-1301

  Michel, Tanja Maria ^a,b,c   Gsell, Wieland ^d   Käsbauer, Ludwig ^b   Tatschner, Thomas ^b   Sheldrick, Abigail Jane ^a   Neuner, Irene ^a   Schneider, Frank ^a,c   Grünblatt, Edna ^b   Riederer, Peter ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c JARA Translational Brain Medicine   (Germany)

^d State Hospital for Psychiatry Psychotherapy and Neurology   (Germany)

Author keywords

Aging; Aldehydehydrogenase; Alzheimer's disease; Dementia; Free radicals; Mitochondria; Oxidative stress

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MITOCHONDRION; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUTAMEN;

EID: 77950344165     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1326     Document Type: Article

References (49)

1. Alonso A, Zaidi C, Novak T, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98, 6923-6928.
2. Haber F, Weiss J (1934) The catalytic decomposition of hydrogen peroxide by iron salts. Proc Roy Soc 147, 332-351.
3. Reed TT, Pierce WM, Markesbery WR, Butterfield DA (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insight into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66-76.
4. Picklo MJ, Montine TJ (2007) Mitochondrial effects of lipidderived neurotroxins. J Alzheimers Dis 12, 185-193.
5. Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, de La Torre R (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 33, 450-458.
6. Sofic E, Sapcanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, Tatschner T, Riederer P (2006) Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. J Neural Transm Suppl 71, 39-43.
7. Chen K, Kazachkov M, Yu PH (2007) Effect of aldehydes derived from oxidative damination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease. J Neural Transm 114, 835-839.
8. Durany N, Muench G, Michel T, Riederer P (1999) Investigations on oxidative stress and therapeutical imlications in dementia. Eur Arch Psychiatry Clin Neurosci (Germ) 249 Suppl 3, 68-73.
9. Michel TM, Thome J, Nara K, Martin D, Camara S, Weijers HG, Riederer P, Koutsilieri E (2004) The role of oxidative stress in the pathogenesis of schizophrenic psychoses - Superoxide Dismutase (SOD)-coenzyme con-centrations in post-mortem brain tissue of schizophrenic patients. J Neural Transm 111, 1191-1201.
10. Ohta S, Ohsawa I (2006) Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J Alzheimers Dis 9, 155-166.
11. Michel TM, Frangou S, Camara S, Tatschner T, Sheldrick AJ, Riederer P, Grünblatt E (2008) Evidence for increased oxidative stress in the thalamus and in the putamen in patients with recurrent depressive disorder - a post-mortem investigation. World J Biol Psychiatry 12, 1-7.
12. Michel TM, Frangou S, Thiemeyer D, Camara S, Zoechling R, Jecel J, Nara K, Brunklaus A, Riederer P (2007) Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a post-mortem study. Psychiatry Res 15, 145-150.
13. ValkoM, Leibfritz D, Moncol J, Cronin MT, Mazur M,Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39, 44-84.
14. Valko M, Morris H, Cronin MT (2005) Metals, toxicity and oxidative stress. Curr Med Chem 12, 1161-1208.
15. Ambroziak W, Pietruszko R (1991) Human aldehyde dehydrogenase activity with aldehyde metabolites of monoamines, diamines and polyamines. J Biol Chem 266, 13011-13018.
16. Forte-McRobbie CM, Pietruszko R (1986) Purification and characterization of human liver "high Km" aldehyde dehydrogenase and its identification as glutamic gamma-semialdehyde dehydrogenase. J Biol Chem 261, 2154-2163.
17. Lindahl R, Evces S (1984) Rat liver aldehyde dehydrogenase. I. Isolation and haracterization of four high Km normal liver isoenzymes. J Biol Chem 259, 11986-11990.
18. Kuhla B, Haase C, Flach K, Lüth HJ, Arendt T, Münch G (2007) Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J Biol Chem 282, 6984-6991.
19. Kuhla B, Boeck K, Schmidt A, Ogunlade V, Arendt T, Münch G, Lüth HJ (2006) Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol Aging 28, 29-41.
20. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, Kitamura S, Namekata K, Miki T, Ohta S (2000) Deficiency in mitochondrial aldehyde dehydrogenase increas es the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun 273, 192-196.
21. Ohta S, Ohsawa I, Kamino K, Ando F, Shimokata H (2004) Mitochondrial ALDH2 deficiency as an oxidative stress. Ann N Y Acad Sci 1011, 36-44.
22. Wang B, Wang J, Zhou S, tan S, He X, Yang Z, Xie YC, Li S, Zheng C, Ma X (2008) The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci 268, 172-175.
23. Wangad B, Wangad J, Zhouad S, Tanad S, Head X, Yangb Z, Xiec YZ, Lib S, Zhengf C, Maade X (2008) The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neural Sci 268, 172-175.
24. Shin IS, Stewart R, Kim JM, Kim SW, Yang SJ, Shin HY, Jung JS, Yoon JS (2005) Mitochondrial aldehyde dehydrogenase polymorphism is not associated with incidence of Alzheimer's disease. Int J Geriatr Psychiatry 20, 1075-1080.
25. Ohsawa I, Nishimaki K, Murakami Y, Suzuki Y, Ishikawa M, Ohta S (2008) Age-dependent neurodegeneration accompanying memory loss in transgenic mice defective in mitochondrial aldehyde dehydrogenase 2 activity. J Neurosci 28, 6239-6249.
26. Picklo MJ, Olson SJ, Markesbery WR, Montine TJ (2001) Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 60, 686-695.
27. Bartzokis G, Tishler TA (2000) MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 46, 821-833.
28. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J (2000) In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57, 47-53.
29. Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N, Savoiardo M, Chiapparini L (2009) Age related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 252, 165-172.
30. WHO (1992) ICD 10, International classification of diseases, Geneva, Switzerland.
31. Tierney MC Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstaten P (1988) The NINCDS-ADRA work group criteria for the clinical diagnosis of probable Alzheimer's disease: clinicopathlogic study of 57 cases. Neurology 38, 359-364.
32. GsellW, Lange KW, Pfeuffer R, Heckers S, Heinsen H, Senitz D (1993) How to run a brain bank. A report from the Austro- German brain bank. J Neural Transm Suppl 39, 31-70.
33. Bradford M(1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
34. Ryzlak MT, Pietruszko R (1987) Purification and characterization of aldehyde dehydrogenase from human brain. Arch Biochem Biophys 255, 409-418.
35. Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 17, 338-393.
36. Marklund Sl, Adolfsson R, Gottfries CG, Winblad G (1985) Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of the Alzheimer type. J Neurol Sci 67, 319-325.
37. Konradi C, Riederer P, Youdim MBH (1986) Hydrogen peroxide enhances the activity of monoamine oxidase type B and not type A. A pilot study. J Neural Transm Suppl 22, 61-73.
38. Grünblatt E, Schlösser R, Fischer p, Fischer MO, Li J, Koutsilierei E,Wichart I, Stermba N, Rujescu D,Möller HJ, AdamcykW, Dittrich B,Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Huber K, Tragl KH, Danielczyk W, Riederer P (2005) Oxidative stress related markers in the "VITA" and the centenarian projects. Neurobiol Aging 26, 429-438.
39. Durany N, Michel T, Jellinger K, Cruz-Sanchez FF, Cervos- Navarro J, Riederer P (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Devl Neurosci 18, 807-810.
40. Michel TM, Nara K, Camara S,Koutsilieri E, Jecel JC, Riederer P (2004) Activity of Xanthine Oxidase in different brain regions of patients with Alzheimer's dementia - a post mortem study. World J Biol Psych 5 Suppl 6212, 86.
41. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G (2001) Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl 61, 193-201.
42. Furuta A, Price DL, Pardo CA (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neuocortex and hippocampus. Am J Pathol 146, 357-1356
43. Pietruszko R, Reed DM, Vallari RC, Major LF, Saini N, Hawley RJ (1981) Brain aldehyde dehydrogenase in human alcoholics and controls. Alcoholism Clin Exp Res 5, 78-84.
44. Fowler CJ, Wiberg A, Oreland L, Marusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49, 1-20.
45. Thome J, Nara K, Foley P, Michel T, Gsell W, Retz W, Rösler M, Riederer P (1997) CNTF genotypes: influence on choline acetyltransferase (ChAT) and acetylcholine esterase (AChE) activities and neurotrophin 3 (NT3) concentration in human post mortem brain tissue. J Hirnforsch 38, 443-451.
46. Wischik CM (2008) O3-04-07: Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 4 Suppl 1, T167.
47. Gillman PK (2008) Methylene blue is a potent monoamine oxidase inhibitor. Can J Anaesth 55, 311-312.
48. Wiesbeck GA, Weijers HG, Wodarz N, Hermann M, Johann M,Keller H, Michel TM,Böning J (2003) Dopamin D 2 (DAD 2) and dopamin D 3 (DAD 3) receptor gene polymorphismus and treatment outcome in alcohol dependence. J Neural Transm 110, 813-820.
49. Sahlmann M, Vieten A, Sheldrick AJ, Haeck M, Schneider F, Michel TM (2010) Early Recognition Centres for Patients at Risk of Developing Schizophrenia in Germany Gesundheitsf ürsorge, epub 4. Januar DOI: 10.1055/s-0029-1242783.